Calcineurin inhibitors (CNI)

DRUG5 trials

Conditions

Antisynthetase SyndromeDisorder Related to Cardiac TransplantationInterstitial Lung Disease (ILD)Kidney TransplantationLiver TransplantationRenal TransplantationTransplantation, Kidney

Phase 3

RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency

CompletedNCT00267189

Novartis PharmaceuticalsLiver Transplantation

Start: 2005-11-30End: 2007-11-30Updated: 2011-04-13

Phase 4

ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients

CompletedNCT00170846

Novartis PharmaceuticalsRenal Transplantation

Start: 2005-02-28End: 2009-10-31Updated: 2015-01-27

Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation

CompletedNCT00377962

Novartis PharmaceuticalsDisorder Related to Cardiac Transplantation

Start: 2005-12-31End: 2010-02-28Updated: 2020-07-30

Unknown Phase

Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

CompletedNCT01656343

Bristol-Myers SquibbKidney Transplantation, Transplantation, Kidney

Start: 2011-10-31End: 2019-08-05Updated: 2022-07-22

A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome

Not yet recruitingNCT07406932

China-Japan Friendship HospitalAntisynthetase Syndrome, Interstitial Lung Disease (ILD)

Start: 2026-02-01End: 2027-07-01Target: 80Updated: 2026-02-12

Related Papers

Patterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidney transplant recipients: An analysis of the Organ Procurement and Transplantation Network database

PLoS ONE2025-01-104 citations

Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression.